Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Scientists solve structure of key protein from Lassa virus

Scientists solve structure of key protein from Lassa virus

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant third quarter revenue decreases 2% to $208.3 million

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection

Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.